Hyperlipidemia and cardiovascular disease: Triglycerides-a revival of cardiovascular risk factor?

Current Opinion in Lipidology

Volumn 22, Issue 4, 2011, Pages 319-321

  Nofer, Jerzy Roch ^a,b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; APOLIPOPROTEIN C; APOLIPOPROTEIN D; APOLIPOPROTEIN E; APOLIPOPROTEIN M; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; NOTE; PATHOGENESIS; PRIORITY JOURNAL;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; HYPERLIPIDEMIAS; META-ANALYSIS AS TOPIC; RISK FACTORS; TRIGLYCERIDES;

EID: 79960631826     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328348a539     Document Type: Note

References (17)

1. Harchaoui KE, Visser ME, Kastelein JJ, et al. Triglycerides and cardiovascular risk. Curr Cardiol Rev 2009; 5:216-222.
2. Kannel WB, Vasan RS. Triglycerides as vascular risk factors: new epidemiologic insights. Curr Opin Cardiol 2009; 24:345-350.
3. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302:1993-2000.
4. Sarwar N, Sandhu MS, Ricketts SL, et al., Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Triglyceridemediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010; 375:1634-1639.
5. Labreuche J, Deplanque D, Touboul PJ, et al. Association between change in plasma triglyceride levels and risk of stroke and carotid atherosclerosis: systematic review and meta-regression analysis. Atherosclerosis 2010; 212:9-15.
6. De Caterina R, Scarano M, Marfisi R, et al. Cholesterol-lowering interventions and stroke: insights from a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2010; 55:198-211.
7. Neil HA, Cooper J, Betteridge DJ, et al., Simon Broome Familial Hyperlipidaemia Register Group. All-cause and cardiovascular mortality in treated patients with severe hypertriglyceridaemia: a long-term prospective registry study. Atherosclerosis 2010; 211:618-623.
8. Mora S, Rifai N, Buring JE, et al. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008; 118:993-1001.
9. Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298:299-308. (Pubitemid 47080484)
10. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008; 300:2142-2152.
11. Langsted A, Freiberg JJ, Tybjaerg-Hansen A, et al. Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. J Intern Med 2010. doi: 10.1111/j.1365-2796.2010.02333.x
12. Varbo A, Nordestgaard BG, Tybjaerg-Hansen A, et al. Nonfasting triglycerides, cholesterol, and ischemic stroke in the general population. Ann Neurol 2011; 69:628-634.
13. Keech A, Simes RJ, Barter P, et al., FIELD study investigators. Effects of longterm fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849-1861.
14. Ginsberg HN, Elam MB, Lovato LC, et al., ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362:1563-1574.
15. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010; 375: 1875-1884.
16. Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med 2010; 363:692-694.
17. Bruckert E, Labreuche J, Deplanque D, et al. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile. A systematic review and metanalysis. J Cardiovasc Pharmacol 2011; 57:267-272.